Therapeutic targeting the loss of the birt-hogg-dube suppressor gene

Xiaohong Lu, Wenbin Wei, Janine Fenton, Michael S Nahorski, Erzsebet Rabai, Anne Reiman, Laurence Seabra, Zsuzsanna Nagy, Farida Latif, Eamonn R Maher

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Brit-Hogg-Dubé (BHD) syndrome, an autosomal dominant familial cancer, is associated with increased risk of kidney cancer. BHD syndrome is caused by loss-of-function mutations in the folliculin (FLCN) protein. To develop therapeutic approaches for renal cell carcinoma (RCC) in BHD syndrome, we adopted a strategy to identify tumor-selective growth inhibition in a RCC cell line with FLCN inactivation. The COMPARE algorithm was used to identify candidate anticancer drugs tested against the NCI-60 cell lines that showed preferential toxicity to low FLCN expressing cell lines. Fifteen compounds were selected and detailed growth inhibition (SRB) assays were done in paired BHD RCC cell lines (UOK257 derived from a patient with BHD). Selective sensitivity of FLCN-null over FLCN-wt UOK257 cells was observed in seven compounds. The most selective growth-inhibitory sensitivity was induced by mithramycin, which showed an approximately 10-fold difference in GI(50) values between FLCN-null (64.2 ± 7.9 nmol/L, n = 3) and FLCN-wt UOK257 cells (634.3 ± 147.9 nmol/L, n = 4). Differential ability to induce caspase 3/7 activity by mithramycin was also detected in a dose-dependent manner. Clonogenic survival studies showed mithramycin to be approximately 10-fold more cytotoxic to FLCN-null than FLCN-wt UOK257 cells (200 nmol/L). Following mithramycin exposure, UOK257-FLCN-null cells were mainly arrested and blocked in S and G(2)-M phases of the cell cycle and low dose of rapamycin (1 nmol/L) potentiated mithramycin sensitivity (1.5-fold in G(2)-M population and 2-fold in G(2)-M period time, 2xGI(50), 48 hours). These results provide a basis for further evaluation of mithramycin as a potential therapeutic drug for RCC associated with BHD.

Original languageEnglish
Pages (from-to)80-9
Number of pages10
JournalMolecular Cancer Therapeutics
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Suppressor Genes
Estrone
Plicamycin
Renal Cell Carcinoma
Therapeutics
Cell Line
Growth
Caspase 7
Null Lymphocytes
Kidney Neoplasms
Sirolimus
Caspase 3
Pharmaceutical Preparations
Cell Division
Neoplasms
Cell Cycle

Keywords

  • Algorithms
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Caspase 3
  • Caspase 7
  • Cell Line, Tumor
  • Cell Survival
  • Drug Screening Assays, Antitumor
  • Gene Expression Regulation, Neoplastic
  • Gene Silencing
  • Genes, Tumor Suppressor
  • Genes, p53
  • Humans
  • Kidney Neoplasms
  • Molecular Targeted Therapy
  • PTEN Phosphohydrolase
  • Plicamycin
  • Proto-Oncogene Proteins
  • Sirolimus
  • Tumor Suppressor Proteins
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Therapeutic targeting the loss of the birt-hogg-dube suppressor gene. / Lu, Xiaohong; Wei, Wenbin; Fenton, Janine; Nahorski, Michael S; Rabai, Erzsebet; Reiman, Anne; Seabra, Laurence; Nagy, Zsuzsanna; Latif, Farida; Maher, Eamonn R.

In: Molecular Cancer Therapeutics, Vol. 10, No. 1, 01.2011, p. 80-9.

Research output: Contribution to journalArticle

Lu, X, Wei, W, Fenton, J, Nahorski, MS, Rabai, E, Reiman, A, Seabra, L, Nagy, Z, Latif, F & Maher, ER 2011, 'Therapeutic targeting the loss of the birt-hogg-dube suppressor gene' Molecular Cancer Therapeutics, vol. 10, no. 1, pp. 80-9. https://doi.org/10.1158/1535-7163.MCT-10-0628
Lu, Xiaohong ; Wei, Wenbin ; Fenton, Janine ; Nahorski, Michael S ; Rabai, Erzsebet ; Reiman, Anne ; Seabra, Laurence ; Nagy, Zsuzsanna ; Latif, Farida ; Maher, Eamonn R. / Therapeutic targeting the loss of the birt-hogg-dube suppressor gene. In: Molecular Cancer Therapeutics. 2011 ; Vol. 10, No. 1. pp. 80-9.
@article{4ab4fd0d857148959107474977191116,
title = "Therapeutic targeting the loss of the birt-hogg-dube suppressor gene",
abstract = "Brit-Hogg-Dub{\'e} (BHD) syndrome, an autosomal dominant familial cancer, is associated with increased risk of kidney cancer. BHD syndrome is caused by loss-of-function mutations in the folliculin (FLCN) protein. To develop therapeutic approaches for renal cell carcinoma (RCC) in BHD syndrome, we adopted a strategy to identify tumor-selective growth inhibition in a RCC cell line with FLCN inactivation. The COMPARE algorithm was used to identify candidate anticancer drugs tested against the NCI-60 cell lines that showed preferential toxicity to low FLCN expressing cell lines. Fifteen compounds were selected and detailed growth inhibition (SRB) assays were done in paired BHD RCC cell lines (UOK257 derived from a patient with BHD). Selective sensitivity of FLCN-null over FLCN-wt UOK257 cells was observed in seven compounds. The most selective growth-inhibitory sensitivity was induced by mithramycin, which showed an approximately 10-fold difference in GI(50) values between FLCN-null (64.2 ± 7.9 nmol/L, n = 3) and FLCN-wt UOK257 cells (634.3 ± 147.9 nmol/L, n = 4). Differential ability to induce caspase 3/7 activity by mithramycin was also detected in a dose-dependent manner. Clonogenic survival studies showed mithramycin to be approximately 10-fold more cytotoxic to FLCN-null than FLCN-wt UOK257 cells (200 nmol/L). Following mithramycin exposure, UOK257-FLCN-null cells were mainly arrested and blocked in S and G(2)-M phases of the cell cycle and low dose of rapamycin (1 nmol/L) potentiated mithramycin sensitivity (1.5-fold in G(2)-M population and 2-fold in G(2)-M period time, 2xGI(50), 48 hours). These results provide a basis for further evaluation of mithramycin as a potential therapeutic drug for RCC associated with BHD.",
keywords = "Algorithms, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Caspase 3, Caspase 7, Cell Line, Tumor, Cell Survival, Drug Screening Assays, Antitumor, Gene Expression Regulation, Neoplastic, Gene Silencing, Genes, Tumor Suppressor, Genes, p53, Humans, Kidney Neoplasms, Molecular Targeted Therapy, PTEN Phosphohydrolase, Plicamycin, Proto-Oncogene Proteins, Sirolimus, Tumor Suppressor Proteins, Journal Article, Research Support, Non-U.S. Gov't",
author = "Xiaohong Lu and Wenbin Wei and Janine Fenton and Nahorski, {Michael S} and Erzsebet Rabai and Anne Reiman and Laurence Seabra and Zsuzsanna Nagy and Farida Latif and Maher, {Eamonn R}",
note = "{\circledC}2010 AACR.",
year = "2011",
month = "1",
doi = "10.1158/1535-7163.MCT-10-0628",
language = "English",
volume = "10",
pages = "80--9",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research",
number = "1",

}

TY - JOUR

T1 - Therapeutic targeting the loss of the birt-hogg-dube suppressor gene

AU - Lu, Xiaohong

AU - Wei, Wenbin

AU - Fenton, Janine

AU - Nahorski, Michael S

AU - Rabai, Erzsebet

AU - Reiman, Anne

AU - Seabra, Laurence

AU - Nagy, Zsuzsanna

AU - Latif, Farida

AU - Maher, Eamonn R

N1 - ©2010 AACR.

PY - 2011/1

Y1 - 2011/1

N2 - Brit-Hogg-Dubé (BHD) syndrome, an autosomal dominant familial cancer, is associated with increased risk of kidney cancer. BHD syndrome is caused by loss-of-function mutations in the folliculin (FLCN) protein. To develop therapeutic approaches for renal cell carcinoma (RCC) in BHD syndrome, we adopted a strategy to identify tumor-selective growth inhibition in a RCC cell line with FLCN inactivation. The COMPARE algorithm was used to identify candidate anticancer drugs tested against the NCI-60 cell lines that showed preferential toxicity to low FLCN expressing cell lines. Fifteen compounds were selected and detailed growth inhibition (SRB) assays were done in paired BHD RCC cell lines (UOK257 derived from a patient with BHD). Selective sensitivity of FLCN-null over FLCN-wt UOK257 cells was observed in seven compounds. The most selective growth-inhibitory sensitivity was induced by mithramycin, which showed an approximately 10-fold difference in GI(50) values between FLCN-null (64.2 ± 7.9 nmol/L, n = 3) and FLCN-wt UOK257 cells (634.3 ± 147.9 nmol/L, n = 4). Differential ability to induce caspase 3/7 activity by mithramycin was also detected in a dose-dependent manner. Clonogenic survival studies showed mithramycin to be approximately 10-fold more cytotoxic to FLCN-null than FLCN-wt UOK257 cells (200 nmol/L). Following mithramycin exposure, UOK257-FLCN-null cells were mainly arrested and blocked in S and G(2)-M phases of the cell cycle and low dose of rapamycin (1 nmol/L) potentiated mithramycin sensitivity (1.5-fold in G(2)-M population and 2-fold in G(2)-M period time, 2xGI(50), 48 hours). These results provide a basis for further evaluation of mithramycin as a potential therapeutic drug for RCC associated with BHD.

AB - Brit-Hogg-Dubé (BHD) syndrome, an autosomal dominant familial cancer, is associated with increased risk of kidney cancer. BHD syndrome is caused by loss-of-function mutations in the folliculin (FLCN) protein. To develop therapeutic approaches for renal cell carcinoma (RCC) in BHD syndrome, we adopted a strategy to identify tumor-selective growth inhibition in a RCC cell line with FLCN inactivation. The COMPARE algorithm was used to identify candidate anticancer drugs tested against the NCI-60 cell lines that showed preferential toxicity to low FLCN expressing cell lines. Fifteen compounds were selected and detailed growth inhibition (SRB) assays were done in paired BHD RCC cell lines (UOK257 derived from a patient with BHD). Selective sensitivity of FLCN-null over FLCN-wt UOK257 cells was observed in seven compounds. The most selective growth-inhibitory sensitivity was induced by mithramycin, which showed an approximately 10-fold difference in GI(50) values between FLCN-null (64.2 ± 7.9 nmol/L, n = 3) and FLCN-wt UOK257 cells (634.3 ± 147.9 nmol/L, n = 4). Differential ability to induce caspase 3/7 activity by mithramycin was also detected in a dose-dependent manner. Clonogenic survival studies showed mithramycin to be approximately 10-fold more cytotoxic to FLCN-null than FLCN-wt UOK257 cells (200 nmol/L). Following mithramycin exposure, UOK257-FLCN-null cells were mainly arrested and blocked in S and G(2)-M phases of the cell cycle and low dose of rapamycin (1 nmol/L) potentiated mithramycin sensitivity (1.5-fold in G(2)-M population and 2-fold in G(2)-M period time, 2xGI(50), 48 hours). These results provide a basis for further evaluation of mithramycin as a potential therapeutic drug for RCC associated with BHD.

KW - Algorithms

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Renal Cell

KW - Caspase 3

KW - Caspase 7

KW - Cell Line, Tumor

KW - Cell Survival

KW - Drug Screening Assays, Antitumor

KW - Gene Expression Regulation, Neoplastic

KW - Gene Silencing

KW - Genes, Tumor Suppressor

KW - Genes, p53

KW - Humans

KW - Kidney Neoplasms

KW - Molecular Targeted Therapy

KW - PTEN Phosphohydrolase

KW - Plicamycin

KW - Proto-Oncogene Proteins

KW - Sirolimus

KW - Tumor Suppressor Proteins

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1158/1535-7163.MCT-10-0628

DO - 10.1158/1535-7163.MCT-10-0628

M3 - Article

VL - 10

SP - 80

EP - 89

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -